ICER pan­el says two ALS drug can­di­dates have 'low' long-term val­ue

ALS is well-known as one of the most dif­fi­cult drug tar­gets, and the US cost-ef­fec­tive­ness watch­dog ICER isn’t quite inch­ing clos­er to en­dors­ing the two can­di­dates.

ICER’s Mid­west CEPAC (Com­par­a­tive Ef­fec­tive­ness Pub­lic Ad­vi­so­ry Coun­cil) met Fri­day to dis­cuss clin­i­cal ev­i­dence on Amy­lyx’s AMX0035 and Mit­subishi Tan­abe Phar­ma Amer­i­ca’s in­tra­venous ver­sion of an old­er ALS med­i­cine, edar­avone.

Af­ter hours of back and forth be­tween pan­elists, ques­tions and pub­lic com­ments, the pan­el vot­ed 13-2 that AMX0035, at its cur­rent sug­gest­ed price of $169,000, would have low long-term val­ue. The same pan­el al­so vot­ed 14-1 that oral edar­avone, at its es­ti­mat­ed WAC of $171,000, would al­so have low long-term val­ue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER